Acura Pharmaceuticals, Inc.

Hercules Corporation

Other

Isp Investments Inc.

Divya Tewari

David Dixon

Vijai Kumar

Dilip B Wadgaonkar

Thomas Durig

Brad Beissner

Yevgeniya A Titova

Tuyen T Nguyen

Todd Andrew Brugel

Yuda Zong

Sangrama Sahoo

The present invention provides a coprocessed excipient composition and a method of producing the same. The coprocessed excipient comprises vinyl lactam derived polymer and a deagglomerated coprocessing agent. The coprocessing agent is fumed silica, colloidal silica or silicon dioxide. The coprocessed excipient is prepared by a continuous process and has a Brookfield cohesion of less than 0.12 kPa, a bulk density of at least 0.249 gram/milliliter and a flow property as measured by Johanson flow rate number increase from 1.1 to 5.0 fold.

Coprocessed silica coated polymer composition

An excipient composition having good bulk density and improved flow characteristics is provided. The present invention particularly provides a coprocessed excipient composition and a method of producing the same. The coprocessed excipient comprises cellulose derived polymer and a deagglomerated coprocessing agent. The coprocessing agent is fumed silica, colloidal silica or silicon dioxide. The coprocessed excipient is prepared in a continuous process and has excellent compactability and improved flow property as measured by Johanson flow rate number increase from 1.1 to 5.0 fold, is characterized by a Brookfield cohesion factor of less than 0.2 kPa and a bulk density of at least 0.249 g/ml.

This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.

Abuse deterrent compositions and methods of making same

The presently disclosed and claimed inventive concept(s) relates to a polymer for enhancing drug performance and improving processability. Specifically, the polymer comprises hydroxypropyl methyl cellulose acetate succinate (HPMC-AS). On the HPMC-AS, the percentage of total succinoyl degree of substitution is less than 12% at C6-OH position and greater than 53% at C3-OH, and the percentage of total acetyl degree of substitution is greater than 32% at C6-OH position.

Pharmaceutical compositions with enhanced performance and improved processability

The present invention relates to a film coating composition used for film coating pharmaceutical tablets, nutritional supplements, confectionary forms and the like. The film coating composition comprises a water soluble film former such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, starches, modified starches and the like and one or more hydrophobic compounds, such as metal salt of higher fatty acids, higher fatty alcohol, natural wax either from vegetable, animal origin or synthetic wax. Optionally, the film coating composition may include plasticizers, colorants, such as pigments and/or flow aids.

Film coating composition from solid powder hydrophobic compounds

This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.

Growing community of inventors

Suffern, NY, United States of America

Divya Tewari